ReviewImmunologic research2006
Following the TRAIL to apoptosis.
Review in Immunologic research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.Medical science monitor : international medical journal of experimental and clinical research · 2012Trial
- Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.Fortune journal of health sciences · 2026Article
- Recent Therapeutic Strategies for Excessive Chondrocyte Death in Osteoarthritis: A Review.Orthopaedic surgery · 2023Review
- TRAIL-Dependent Resolution of Pulmonary Fibrosis.Mediators of inflammation · 2018Article
- Apoptosis activation in human carious dentin. An immunohistochemical study.European journal of histochemistry : EJH · 2015Article
- The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.Journal of cancer research and clinical oncology · 2011Article
- Article
- TNF superfamily gene polymorphism as prognostic factor in early breast cancer.Journal of cancer research and clinical oncology · 2010Article
- The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.Anti-infective agents in medicinal chemistry · 2009Article
- Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.Cancer research · 2009Article
- Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.Cancer immunology, immunotherapy : CII · 2008Article
- Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.Molecular cancer therapeutics · 2008Article
- Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.Current cancer drug targets · 2008Review
- Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2007Review
- Increased expression of inhibitor of apoptosis proteins in atherosclerotic plaques of symptomatic patients with carotid stenosis.Experimental and molecular pathology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-beta1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a "miracle" drug for cancer because of its ability to selectively kill cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.